The increase in the abuse of illicit drugs in recent years is a matter of growing concern within society. The most widely used technique for detecting the consumption of illicit drugs is that of urine analysis, usually referred to as drug testing, and the results generated can be used to establish if an individual has consumed drugs within a time period prior to the collection of the sample.
Drug testing has been progressively extended from its original clinical setting, where results were utilised to improve the therapeutic care of the addict, to other sectors of society such as workplace safety, forensic science, prisons, insurance medicals, driving under the influence of drugs and anti-doping programmes in sports. In certain situations, when medico-legal implications have to be considered, a positive identification can have a serious impact on the individual's freedom and livelihood.
The European countries have different approaches to the drugs of abuse problem. Consequently, each country has a different approach to drug testing and to the implementation of measures for ensuring the quality of results. External Quality Assessment Programmes on drug testing are established in certain European countries such as Italy, Spain/France, the UK, the Netherlands, Belgium/Luxembourg, Germany and the Scandinavian countries. However, the requirements made of laboratory drug testing, even within the same country, vary substantially, e.g. forensic, clinical, workplace. This situation, coupled to the national variation in policies, practices and legal systems, inevitably complicates any attempt to implement the desire of the European Union to establish a single internal market and the associated free circulation of workers by the end of the century.
In response to a proposal by the Spanish Presidency in the first half of 1989, The Conclusions of the Council and the Ministers of Health of the Member States meeting within the Council of 16th May 1989 concerning the reliability of tests to detect the use of illicit drugs (89/C I85/2nd July 1989) were adopted. In those conclusions, reference was made to the evaluation of the extent and circumstances where drug testing was developing in Europe, the consequences for individuals with positive analytical results and their compatibility with the new situation created by the single European market. Specifically, the Council invited the Commission to first:
(a) Examine the criteria currently used for reporting positive results, including the need to distinguish between screening and confirmation (b) Examine the existing Quality Assurance programmes (c) Check on the validity of Certified Reference Materials for illicit drugs and their metabolites.
In order to provide the information requested by the resolution: (1) The Commission of the European Community first sent a questionnaire to the appropriate authorities of the EU Member States. This questionnaire dealt with the legal and regulatory aspects of testing body fluids to detect the use of illicit drugs. The questionnaire also enquired into the testing practices of the State as an employer. (2) A second questionnaire was sent to laboratories involved with drugs of abuse testing. This task was conducted in 1991 by Professor R A de Zeeuw (Groningen, the Netherlands) and dealt with the substances the laboratory tested for, which cut-off values" were applied, the test methods used, whether the laboratory took duplicate samples and how the laboratory handled the interpretation and the transmission of results. The participation of laboratories in External Quality Assessment Programmes was also investigated. (3) A third step was a survey on the quality of analysis carried out by a representative number of European laboratories (Survey undertaken in the European Community to examine the reliability of urinalyses carried out to detect the use of illicit drugs, Part I and II; 1993 -1994 . The survey was supported by both the DG V/F/I of the Commission of the European Communities and the Institut Municipal d'lnvestigaci6 Medica (IMIM), Barcelona, Spain. A set of control urines together with a comprehensive Analytical Results form, which requested important methodological information was distributed to about 270 European laboratories. In addition, in survey Part II, laboratories were provided with reference materials which included reference substances and freeze dried urine samples of known composition which enabled the laboratories to set up internal quality control procedures for their analytical procedures. In both cases (Survey Part I and II) laboratories were requested to analyse the samples and to return their results on the Analytical Results forms provided, within 5 weeks of receiving the test samples. The results were evaluated at the IMIM and the final report was returned to both the Commission and all of the participating laboratories. The con-·The cut-off value is the decision level that determines whether a sample result is termed positive .... The cut-off value is different from the limit of detection, which is the smallest amount of compound that can be detected by the system.' Clin Biochem 1997: 34 tent of each test sample was disclosed only after the laboratory results of all participating laboratories had been received.
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As a follow up to these activities the Commission decided to provide financial support to a project: Drugs of Abuse Testing, Part III; 1996-1997 co-ordinated at the IMIM. This project has one main objective: to ensure an adequate dissemination of the results generated by previous studies into the reliability of drug testing in body fluids, at technical, scientific and institutional levels.
Within the project plan, the preparation of a document to be discussed at a workshop meeting in Barcelona on 14-15 June 1996, by the Toxicology Experts Working Group was one very important objective.
Following a comprehensive assessment of the information collected from previous survey results, the Toxicology Experts Working Group drew up recommendations so as to provide homogeneous analytical criteria and reference procedures which should be implemented whenever drugs of abuse testing programmes are performed within the European Union.
This document will focus specifically on urine analysis for the detection of illicit drugs at the workplace. Other related fields such as forensic and clinical toxicology or insurance medicals, where drug testing also takes place may also benefit from these recommendations. The possibility of specific recommendations in these fields should be addressed separately.
RECOMMENDAnONS
The recommendations outlined in the following five sections cover the major issues relevant to a drug testing laboratory. However, other aspects not included in these recommendations such as the reporting of results and the implementation of employee rehabilitation programmes for individuals testing positive for a given drug, are equally important for the successful implementation of a drug testing programme.
(1) Sample handling and chain of custody The overall process of drugs of abuse testing must comply with strict procedures to ensure the preservation of the sample's integrity, to maintain confidentiality at all times and to guarantee the validity of test results. Such objectives are ensured by chain of custody procedures which involve the administrative tracking of all steps in the handling and storage of the urine sample from its collection through to its disposal.
In principle, split portions of the collected sample (aliquots A and B) should be provided so as to permit counter analysis if required. The Aaliquot should be analysed by the testing laboratory, whereas the B-aliquot should be stored under adequate conditions for a predetermined time for subsequent counter analysis," if necessary.
The latter analysis may be performed by either the original testing laboratory or by another qualified laboratory.
Recommendations
Sample collection procedures should guarantee the individual privacy of the donor unless the procedure calls for a witnessed collection.
The use of a split sample (A and B aliquots)
is preferred, with the B-aliquot reserved for counter analysis. 3 Drug testing laboratories should preferably be able to perform a full analysis, i.e. screening + identification + quantification, and if necessary counter analysis. Nevertheless, it is acceptable for the full task of screening and confirmation to be accomplished by a co-ordinated relationship between two laboratories provided that the inter-laboratory transfer of samples is performed with strict adherence to chain of custody procedures. 4 All procedures performed during the collection, transportation, analysis, interpretation of the results, storage and eventual disposal of the sample must be clearly documented and must ensure: Detection of illicit drugs in urine 341 6 Samples not complying with the correct collection, transportation and storage procedures should be rejected.
Note: If a sample is split into aliquots, then the above recommendations apply to each aliquot.
(2) Cut-off values It is common practice in drugs of abuse analysis to apply the decision limits used as threshold values (cut-off values) for the categorization of results (and individuals) as indicative (positive) or non indicative for the consumption of a drug. The cut-off concentration values are of primary importance for the people being tested, particularly when the ethical, social and legal implications of a positive result are considered. From other information collected from the questionnaires and surveys implemented in the European Union over the last few years, several facts have to be taken into consideration.
• Cut off values routinely applied by laboratories are influenced to a greater extent by the analytical sensitivity of the methodology being used than by the clinical or toxicological significance. • There is substantial variability both between and within European Union Member States regarding the analytical cut-off values applied for reporting positive results for a given group of drugs. Great confusion is observed in the reporting cut-off values for the identification of specific substances.
Given the current situation there is a need to harmonize cut-off values within the Member States of the European Union, and these values should be used as positive identification criteria for each substance or group of substances.
Recommendations
When reporting results, cut-off values should be formally stated. 2 The cut-off concentration values in Table 1 are recommended for Workplace Drug Testing (regular updating of these proposals, either for the drugs included in Table I or for more specific applications should be carried out).
(3) Analytical methodology Drugs of abuse testing usually includes a two step process: a preliminary screening procedure for groups of substances and a confirmation procedure for the identification of specific de fa Torre et af. IS MDMA = 3,4-methylenedioxymethamphetamine MDA = 3,4-methylenedioxyamphetamine MDEA = 3,4-methylenedioxyethylamphetamine II-nor-9-COOH-L\9-THC = II-nor-L\9-tetrahydrocannabinol-9-carboxylic acid. "Currently available immunoassay tests are reported to have major dilTerences as to their specificity. Great attention should be paid to the selection and proper use of such kits. bThe cut-off values for screening tests generally account for more then one compound supposed to be present in the tested urine. The higher the specificity of the screening procedure, the higher the probability that the actual screening cut-off values approach the concentration of a single marker compound. "The evaluation of the results obtained when screening opiates with high specificity immunoassay tests for free morphine at concentrations just below the cut-off value will benefit from additional screening after performing hydrolysis of the sample. cf[he establishment of the presence of some specific substances may be useful for the elTective interpretation of results (i.e. 6-monoacetylmorphine and codeine for opiates; ecgonine methyl ester for cocaine).
"Free + conjugated morphine = total morphine (this concentration is obtained only after sample hydrolysis).
!The detection of cocaine base ('crack') abuse will require lower cut-off values. KThe need for specific screening assays addressing all the designer drugs and/or their metabolites, e.g. the ring substituted amphetamines, should be addressed.
substances (drugs and/or their metabolites). Sometimes a quantitative analytical approach for the specific substances is also performed. From the previous surveys performed by the Experts Working Group amongst laboratories within the European Union, the following points were identified.
• Most laboratories performed reasonably well when using immunological analytical techniques when screening for groups of drugs. • Application of chromatographic analytical techniques for the specific identification of substances was shown to be problematic for certain laboratories. • The quantitative analytical approach for specific substances is performed by a relatively low percentage of laboratories. Nevertheless, all those laboratories performing the quantification of drugs of abuse had the overall best performance in the surveys when compared to those laboratories performing only screening or screening coupled to specific identification procedures. There were important problems in the quantifica-Ann Clin Biochem 1997: 34 tion of opiates and cannabinoids, Gas chromatography coupled to mass spectrometry (GC/MS), using deuterated drug analogues as internal standards, showed the best performance for the quantification of drugs of abuse. • The availability of reference substances improved the performance of laboratories in both the identification and the quantification of drugs tested.
Validated immunoassays are recommended for screening purposes. 2 Chromatographic methods coupled to mass spectrometry are recommended for the identification of specific substances. 3 In order to improve the overall process, the quantification of drugs of abuse in biological fluids is recommended. When using mass spectrometry, the use of isotopically labelled internal standards is preferred. 4 Reference materials must be available in any laboratory performing workplace testing for drugs of abuse. (4) Educational requirements/aspects The major problems identified in the previous surveys were:
(a) The improper set-up of chromatographic techniques (b) The variation in the cut-off values used, especially for specific drug identification, indicates a clear misunderstanding of the concept of cut-off (c) There were major difficulties in the interpretation of results, particularly for the opiates.
These observations clearly indicate that ongoing educational training, including regular participation in External Quality Assessment Programmes, is required by personnel involved in drugs of abuse testing. At present, there is a greater consolidation of EQAPDAT in Europe and the number of participating laboratories is probably higher than in the past. A great variability is observed amongst European EQAPDAT with different emphasis on issues such as education and specific areas of drug testing, e.g. clinical.
Whereas most of the current programmes cover different drug testing applications, which is very useful from an educational perspective, a lack of actual Proficiency Testing Programmes (PTP) is observed. PTP differ from EQAPDAT primarily on the mandatory vs voluntary aspects of the participation and on how the results of the performance test affects the laboratory. Participation of laboratories in EQAPDAT is necessary but not sufficient to guarantee the reliability of the results, which is of paramount importance in drugs of abuse testing. Conversely, PTP are desirable in the context of laboratory accreditation.
Results from the surveys suggest that, in Europe, laboratories involved in Workplace Testing need some form of accreditation in the very near future. Common Quality Assurance systems for chemical laboratories generally cover many points already dealt with in these recommendations. However, in drugs of abuse analysis, the analytical approach, cut-off values and the interpretation of positive results, as well as issues such as sample integrity and chain of custody are of particular importance and should be strongly taken into consideration.
Laboratories performing workplace testing should be accredited according to EN45001/ ISO Guide 25. 2 The recommendations contained in the present document can form the basis for Gilliard (EC), P Lafargue (France), P Mangin (France), K Muller (Germany), M D Osselton (UK), E Sternieri (Italy), Th van de Venne (EC). The project received financial support from the European Commission (contract: 96 CVVF2-201-0).
Neither the European Commission nor any person acting on its behalf is liable for any use made of the above information.
